Background: Neuroblastoma (NB) is the most common extracranial pediatric solid tumor with a highly variable clinical course, ranging from spontaneous regression to life-threatening disease. Survival rates for high-risk NB patients remain disappointingly low despite multimodal treatment. Thus, there is an urgent clinical need for additional biomarkers to improve risk stratification, treatment management, and survival rates in children with aggressive NB.
CITATION STYLE
Yáñez, Y., Grau, E., Rodríguez-Cortez, V. C., Hervás, D., Vidal, E., Noguera, R., … Castel, V. (2015). Two independent epigenetic biomarkers predict survival in neuroblastoma. Clinical Epigenetics, 7(1). https://doi.org/10.1186/s13148-015-0054-8
Mendeley helps you to discover research relevant for your work.